Terms: = Sarcomas AND HER1, YOR227W
13 results:
1. Polypharmacology-based kinome screen identifies new regulators of KSHV reactivation.
Olson AT; Kang Y; Ladha AM; Zhu S; Lim CB; Nabet B; Lagunoff M; Gujral TS; Geballe AP
PLoS Pathog; 2023 Sep; 19(9):e1011169. PubMed ID: 37669313
[TBL] [Abstract] [Full Text] [Related]
2. Dacomitinib: an investigational drug for the treatment of glioblastoma.
Sepúlveda JM; Sánchez-Gómez P; Vaz Salgado MÁ; Gargini R; Balañá C
Expert Opin Investig Drugs; 2018 Oct; 27(10):823-829. PubMed ID: 30247945
[TBL] [Abstract] [Full Text] [Related]
3. Antitumour effects and mechanisms of action of the panHER inhibitor, dacomitinib, alone and in combination with the STAT3 inhibitor, S3I-201, in human sarcoma cell lines.
Wang X; Goldstein D; Crowe PJ; Yang JL
Int J Oncol; 2018 Jun; 52(6):2143-2154. PubMed ID: 29620166
[TBL] [Abstract] [Full Text] [Related]
4. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
[TBL] [Abstract] [Full Text] [Related]
5. [Carcinosarcoma of the breast a rare entity with fatal prognosis. One case report].
Villalón-López JS; Souto-del Bosque R; Alonso-Briones MV; Trujillo-de Anda AP
Cir Cir; 2013; 81(4):328-32. PubMed ID: 25063898
[TBL] [Abstract] [Full Text] [Related]
6. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
[TBL] [Abstract] [Full Text] [Related]
7. A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens.
Ray-Coquard I; Le Cesne A; Whelan JS; Schoffski P; Bui BN; Verweij J; Marreaud S; van Glabbeke M; Hogendoorn P; Blay JY
Oncologist; 2008 Apr; 13(4):467-73. PubMed ID: 18448563
[TBL] [Abstract] [Full Text] [Related]
8. [Molecular diagnostic and targeted therapy--"Barking dogs are going to bite": presentations from the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta 2006].
Rody A; Loibl S; Kaufmann M
Zentralbl Gynakol; 2006 Oct; 128(5):233-41. PubMed ID: 17001557
[TBL] [Abstract] [Full Text] [Related]
9. Mammary NOS-type sarcoma with CD10 expression: a rare entity with features of myoepithelial differentiation.
Leibl S; Moinfar F
Am J Surg Pathol; 2006 Apr; 30(4):450-6. PubMed ID: 16625090
[TBL] [Abstract] [Full Text] [Related]
10. Expression of her1/EGFR protein in human soft tissue sarcomas.
Yang JL; Hannan MT; Russell PJ; Crowe PJ
Eur J Surg Oncol; 2006 May; 32(4):466-8. PubMed ID: 16524687
[TBL] [Abstract] [Full Text] [Related]
11. Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach.
Moinfar F; Gogg-Kamerer M; Sommersacher A; Regitnig P; Man YG; Zatloukal K; Denk H; Tavassoli FA
Am J Surg Pathol; 2005 Apr; 29(4):485-9. PubMed ID: 15767802
[TBL] [Abstract] [Full Text] [Related]
12. The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Knight LA; Di Nicolantonio F; Whitehouse P; Mercer S; Sharma S; Glaysher S; Johnson P; Cree IA
BMC Cancer; 2004 Nov; 4():83. PubMed ID: 15560844
[TBL] [Abstract] [Full Text] [Related]
13. Cooperative activity between HER oncogenes and the tumor suppressor IRF-1 results in apoptosis.
Kirchhoff S; Hauser H
Oncogene; 1999 Jun; 18(25):3725-36. PubMed ID: 10391680
[TBL] [Abstract] [Full Text] [Related]
